Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Research & Development In Brief

This article was originally published in The Tan Sheet

Executive Summary

Fish oil may cut breast cancer risk: Use of fish oil supplements reduces the risk of breast cancer in a seven-year study of 35,016 women aged 50 to 76 years in the Vitamins and Lifestyle cohort. But the study in the July issue of Cancer Epidemiology, Biomarkers and Prevention points out the use of other "specialty" supplements taken for menopausal symptoms, such as black cohosh, dong quai, soy and St. John's wort, were not similarly associated with reduced breast cancer risk. Researchers from the Fred Hutchinson Cancer Research Center and the University of California also say fish oil use was associated with reduced risk of invasive ductal, but not lobular, carcinoma. They hypothesize fish oil's benefit may come from its anti-inflammatory properties. Despite the inverse association between some breast cancer risk and fish oil use, the researchers do not advocate promoting the substance for prevention because their work was a first prospective study and does not consider timing of exposure or dose. Future studies are necessary, they add

You may also be interested in...

S-P Brings New Laxative Class To OTC Market Under Braintree Licensing Deal

Schering-Plough will position Braintree Laboratories' MiraLAX laxative as an effective treatment for occasional constipation without "harsh" side effects linked to other OTC laxative products

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts